Hormonal contraception: Current state and new developments;HORMONALE KONTRAZEPTION: AKTUELLER STAND UND NEUENTWICKLUNGEN

Gynakologe

Volumn 31, Issue 5, 1998, Pages 417-425

  Braendle, W ^a   Kleinkauf Houcken, A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; DIENOGEST; ESTRADIOL; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LOW DOSE ORAL CONTRACEPTIVE; NORETHISTERONE; NORGESTREL; PROGESTERONE;

DRUG SAFETY; ENDOMETRIUM; FAMILY PLANNING; FEMALE; HORMONAL CONTRACEPTION; HUMAN; LIVER METABOLISM; ORAL CONTRACEPTION; REVIEW; RISK; RISK ASSESSMENT;

EID: 0031810363     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001290050282     Document Type: Review

References (40)

1. Bannemerschult R, Hanker JP, Wunsch C, Fox P, Albring M, Brill K (1997) A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control and safety of a new low dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel over 6 treatment cycles. Contraception
2. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP (1995) Enhancement by factor V Leidenmutation of risk of deep-vein-Thrombosis associated with oral contraceptives containing third generation progestagen. Lancet 346. 1593-1595
3. Braendle W (1995) Orale Kontrazeption - Nutzen und Risiken. Arch Gynecol Obstet 257: 532-536
4. Breckwoldt M, Dusterberg B (Hrsg) (1988) Gestodene, a new direction in oral contraception. The Parthenon Publishing Group
5. Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM) (1995) Anwendungsbeschränkungen für orale Kontrazeptiva angeordnet. Pressemitteilung, 6 November 1995
6. Campagnoli C, Biglia N, Giai M, Sismondi P (1997) Gestagene und Mamma. Progestins and breast cancer risk. Zentralblatt Gynakol 119 38-42
7. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727
8. Dieben TOM, op ten Berg MT, Coelingh Bennink HJT (1994) Zykluskontrolle und Nebenwirkungen eines neuen oralen mikrophasischen Kontrazeptivums. Arzneimittel-Forschung 877-879
9. (1997) Balanced view of risk of oral contraceptives. The Lancet 350: 1566
10. Farmer RDT, Preston TD (1995) The risk of venous thromboembolism associated with low estrogen oral contraceptives. J Obstet Gynecol 15: 195-200
11. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR (1997) Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 349: 83-88
12. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH (1996) The novel Progestin Drospirenone and its natural counterpart Progesterone: Biochemical profile and antiandrogenic potential. Contraception 54: 243-251
13. Godsland I, Gangar K, Walton C et al. (1993) Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42. 846-853
14. von Holst T, Schramm G (Hrsg) Norethisteron zur oralen Kontrazeption und Substitution. Schattauer, Stuttgart New York
15. Hsueh AJW (1995) Designer contraceptive pills. Human Reprod 10: 1997-2000
16. Jick H, Jick SS, Gurewich V, Myers WW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589-1593
17. Keck C, Neulen J, Breckwoldt M (1997) Hormonale Kontrazeption. In: Praxis der Frauenheilkunde, Bd. I Thieme, Stuttgart New York
18. Keller PJ (1991) (Hrsg) Aktuelle Aspekte der hormonalen Kontrazeption. Karger, Basel
19. Kuhl H, Jung-Hoffmann C (1996) Kontrazeption. In: Bucherei des Frauenarztes, Bd 52. Enke, Stuttgart New York
20. Kuhnz W, Schutt B, Woloszezak R (1994) Influence of changes in the concentration of sex hormone-binding globulin in human serum on the protein binding of the contraceptive steroid levonorgestrel, 3-keto-desogestrel and gestodene. J Steroid Biochem Mol Biol 48: 573-580
21. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO (1996) The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 54: 5-13
22. Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M (1996) Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 312: 88-90
23. Lewis MA, Heinemann LAJ, Spitzer WO, MacRae KD, Bruppacher R (1997) The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Contraception 56 129-140
24. Lidegaard O (1993) Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Br Med J 306. 956-963
25. Loch EG, Schramm G (1995) (Hrsg) Chlormadinonacetat bei Androgenisierungserscheinungen. Stellenwert in der Praxis. Schattauer, Stuttgart New York
26. Luukkainen T, Lahteenmaki P, Tovionen J (1990) Levonorgestrel-releasing intrauterine device. Ann Med 22: 85-90
27. Newton JR (1995) Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1: 231-263
28. Newton JR (1990) (Hrsg) Mercilon a new area in low-dose oral contraception. The Parthenon Publishing Group
29. Rabe T, Feldmann K, Grunwald K, Runnebaum B (1995) Lebertumoren bei Frauen unter Anwendung von oralen hormonalen Kontrazeptiva - Kurzmitteilung. Zentralbl Gynakol 117. 153-156
30. Rabe T, Nitschke DC, Runnebaum B (1997) The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. Europ J Contraception Reprod Health Care 2: 39-51
31. Rosenberg L, Begaud B, Bergman U et al. (1996) What are the risks of third-generation oral contraceptives? Are third-generation oral contraceptives safe? Hum Repr 11: 687-688
32. Rosenberg L, Palmer JR, Sands MI, Grimes C, Bergman U, Daling J, Mills A (1997) Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 177. 707-715
33. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L (1997) First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 56: 141-146
34. Spitzer WO (1997) The 1995 pill scare revisited: anatomy of a non-epidemic. Hum Reprod 12: 2347-2357
35. Taubert HD, Kuhl H (1995) (Hrsg) Kontrazeption mit Hormonen. Thieme, Stuttgart New York
36. Teichmann AT (1995) (Hrsg) Dienogest. Präklinik und Klinik eines neuen Gestagens. De Gruyter, Berlin New York
37. Teichmann AT, Schulte-Wintrop E, Lorkowski G (1998) Theoretische und klinische Basis einer weiteren Dosisreduktion levonorgestrelhaltiger oraler Kontrazeptiva - Diskussion der Ergebnisse klinischer Prüfungen mit LNG 100/EE 20. In: Teichmann AT, Corbin A (Hrsg) Levonorgestrel. Thieme, Stuttgart New York, S 109-119
38. WHO-Scientific Group Meeting (1997) Cardiovascular disease and steroid hormone contraceptives. Weekly Epidemiological Record 48: 361-363
39. World Health Organization (1995) Collaborative study of cardiovascular disease and steroid hormone contraception: Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 346: 1575-1581
40. World Health Organization (1995) Collaborative study of cardiovascular disease and steroid hormone contraception: Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582-1588